Verve Therapeutics operates as a subsidiary enterprise following its acquisition by the major pharmaceutical corporation Eli Lilly and Company. Prior to the completion of this multi-billion-dollar corporate buyout, Verve functioned as a publicly traded clinical-stage biotechnology company owned by a diverse collective of institutional investors, mutual funds, and retail public shareholders. Following the successful completion of the acquisition agreement by Eli Lilly, the company became an integrated part of Lilly's extensive global research and pharmaceutical development portfolio, shifting its operational governance under the strategic oversight of the parent healthcare conglomerate.